Markers of bone turnover in prostate cancer

Cancer Treatment Reviews

Volumn 27, Issue 3, 2001, Pages 187-192

  Garnero, P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIBODY; ASPARTIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; PAMIDRONIC ACID; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; BIOCHEMISTRY; BONE DISEASE; BONE MATRIX; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS LINKING; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOASSAY; ISOMERISM; LONGITUDINAL STUDY; MALE; MEASUREMENT; MONITORING; OSSIFICATION; OSTEOLYSIS; OSTEOSCLEROSIS; PREVALENCE; PROSTATE CANCER; PROTEIN PROCESSING; SENSITIVITY AND SPECIFICITY; SERUM; URINE;

EID: 0035022942     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0213     Document Type: Article

References (36)

1. R.E. Coleman Monitoring of bone metastases Eur J Cancer 34 1998 252 259
2. J.J. Pollen K.F. Witztun W.L. Ashburn The flare phenomenon on radionuclide bone scan in metastatic prostate cancer Am J Radiother 142 1984 773 776
3. M. Pecherstorfer J. Zimmer-Roth T. Shilling The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium in neoplastic bone disease J Clin Endocrinol Metab 80 1995 97 103
4. S.A. Charhon M.C. Chapuy E.E. Delvin A. Valentin-Opran C.M. Edouard P.J. Meunier Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia Cancer 51 1983 918 924
5. G.H. Urwin R.C. Percival S. Harris M.N.C. Beneton J.L. Williams S.A. Kanis Generalised increase in bone resorption in carcinoma of prostate Eur J Urol 57 1985 721 723
6. N.W. Clarke J. McClure N.J.R. George Morphometric evidence for bone resorption and replacement in prostate cancer Brit J Urol 68 1991 74 80
7. S. Adami Bisphosphonate in prostate cancer Cancer 80 1997 1674 1679
8. J.A. Lorente J. Morote C. Raventos G. Encabo H. Valenzuela Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer J Urol 155 1996 1348 1351
9. S. Akimoto Y. Furuya K. Akakura H. Ito Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastases Endocrine J 45 1998 97 104
10. T. Kylmala J. Risteli I. Elomaa Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer Br J Cancer 71 1995 1061 1064
11. H. Maeda M. Koizumi K. Yoshimura T. Yamauchi T. Kawai E. Ogata Correlation between bone metabolic markers and bone scan in prostatic cancer J Urol 157 1997 539 543
12. K-I. Yoshida S. Sumi K. Arai Serum concentration of type I collagen metabolities as a quantitative marker of bone metastases in patients with prostate cancer Cancer 80 1997 1760 1767
13. J. Nakashima M. Sumitomo A. Miyajima The value of serum carboxyterminal propeptide of type I procollagen in predicting bone metastases in prostate cancer J Urol 157 1997 1736 1739
14. M. Koizumi H. Maeda K. Yoshimura T. Yamauchi T. Kawai E. Ogata Dissociation of bone metabolic markers in bone metastasis of prostate cancer Br J Cancer 75 1997 1601 1604
15. P.D. Delmas B. Demiaux L. Malaval M.C. Chapuy P.J. Meunier Serum bone-GLA-protein is not a sensitive marker of bone turnover in Paget’s disease of bone Calcif Tissue Int 38 1986 60 61
16. K.K. Myamoto S.A. McSkerry S.A. Robins J. Besterman J.L. Mohler Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma J Urol 151 1994 909 913
17. M. Sano K. Kushida M. Takahashi Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastases Br J Cancer 70 1994 701 703
18. S-I. Takeuchi K. Arai H. Saitoh K-I. Yoshida M. Miura Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastases in patients with prostate cancer J Urol 156 1996 1691 1695
19. P. Garnero W.J. Shih E. Gineyts D. Karpf P.D. Delmas Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate J Clin Endocrinol Metab 79 1994 1693 1700
20. R. Hannon A. Blumsohn K. Naylor R. Eastell Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability J Bone Miner Res 13 1998 1124 1133
21. J. Risteli I. Elomaa S. Niemi A. Novamo L. Risteli Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation Clin Chem 39 1993 635 640
22. H. Koga S. Naito S. Koto Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen (1CTP), in the assessment and monitoring of bone metastasis in prostate cancer Prostate 39 1999 1 7
23. C. Hassager L.T. Jensen J. Podenphant K. Thomsen C. Christiansen The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of Nandrolone decanoate and hormone replacement therapy Calcif Tissue Int 54 1994 30 33
24. Y. Nishi L. Atley D.E. Eyre Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation J Bone Miner Res 14 1999 1902 1908
25. P. Garnero O. Borel I. Byrjalsen The collagenolytic activity of cathepsin K is unique amongst mammalian proteinases J Biol Chem 273 1998 32347 32352
26. M. Bonde P. Garnero C. Fledelius P. Qvist P.D. Delmas C. Christiansen Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an eight amino acid sequence of the C-telopeptide of type I collagen J Bone Miner Res 12 1997 1028 1034
27. C. Rosenquist C. Fledelius S. Christgau Serum Crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 44 1998 2281 2289
28. P. Garnero J. Buchs J. Zekri R. Rizzoli R.E. Coleman P.D. Delmas Markers of bone turnover for the management of patients with bone metastases from prostate cancer Br J Cancer 82 2000 858 864
29. C. Fledelius A.H. Johnsen P.A.C. Cloos M. Bonde P. Qvist Characterization of urinary degradation products derived from Type I collagen J Biol Chem 272 1997 9755 9763
30. P.A.C. Cloos C. Fledelius Collagen fragements in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential Biochem J 345 2000 473 480
31. P. Garnero C. Fledelius E. Gineyts C-M. Serre E. Vignot P.D. Delmas Decreased β isomerisation of C-telopeptides of type I collagen in Paget’s disease of bone J Bone Miner Res 12 1997 1407 1415
32. P. Garnero E. Gineyts A.V. Shaffer S. Seaman P.D. Delmas Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease Arthritis Rheum 41 1998 354 360
33. J.J. Vinholes Op Purohit M.E. Abbey R. Eastell R.E. Coleman Relationships between biochemical and symptomatic response in a double-blind trail of pamidronate for metastatic disease Ann Oncol 8 1997 1243 1250
34. A. Bellahcène M.P. Merville V. Castronovo Expression of bone sialoprotein, a bone matrix protein, in human breast cancer Cancer Res 54 1994 2823 2826
35. I.J. Diel E.F. Solomayer M.J. Seibel Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastases Clin Cancer Res 5 1999 3914 3919
36. D. Waltegny A. Bellahcène I. Van Reit Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer J Natl Cancer Inst 90 1998 1000 1008